Intravenous thrombolysis for acute @entity64 in the elderly: data from the Baden-Wuerttemberg XXXX registry.

@entity1 @entity64 @entity5275 @entity23656
BACKGROUND AND PURPOSE: In Europe @entity5275 ( @entity5275 ) for @entity64 is still not approved for @entity1 aged >80 years. However, elderly @entity1 are frequently treated based on individual decision making. In a retrospective observational study a consecutive and prospective @entity64 registry in southwest Germany was analysed. METHODS: The data registry collected 101 349 @entity1 with @entity64 hospitalized from January 2008 to December 2012. Of these, 38 575 (38%) were aged 80 years and older and 10 286 (10.1%) underwent @entity5275 . Favourable outcome at discharge was defined as modified @entity23656 or not worse than prior to @entity64 . Multiple logistic regression models stratified by 10-year age groups were used to assess the relationship between @entity5275 and mRS at discharge, adjusted for @entity1 characteristics, admitting facility and length of hospital stay. RESULTS: The highest @entity5275 rate was 15% in @entity1 aged <50 years, with a continuous decline down to 8% in @entity1 aged >= 90 years. Adjusted odds ratios and 95% confidence intervals for @entity1 80-89 years of age were 2.20 (1.95-2.47) (P < 0.0001) and 1.25 (0.88-1.78) (P = 0.21) for @entity1 >90 years of age, compared to @entity1 of the same age decade not treated with @entity5275 . CONCLUSIONS: The evidence from routine hospital care in southwest Germany indicates that @entity5275 is an effective treatment also for aged @entity1 with @entity64 in an age range between 80 and 89 years. Although no clear evidence for the effectiveness of @entity5275 beyond 90 years was found, treatment should also be carefully considered in these @entity1 . High age should not discourage from treatment.
